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Abstract: Bipolar disorders (BDs) are prevalent mental health illnesses that affect about 1–5% of
the total population, have a chronic course and are associated with a markedly elevated premature
mortality. One of the contributors for the decreased life expectancy in BD is suicide. Accordingly, the
rate of suicide among BD patients is approximately 10–30 times higher than the corresponding rate in
the general population. Extant research found that up to 20% of (mostly untreated) BD subjects end
their life by suicide, and 20–60% of them attempt suicide at least one in their lifetime. In our paper
we briefly recapitulate the current knowledge on the epidemiological aspects of suicide in BD as well
as factors associated with suicidal risk in BD. Furthermore, we also discuss concisely the possible
means of suicide prevention in BD.
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1. Introduction
With a lifetime prevalence of 1.3–5.0%, type-I and -II bipolar disorders (BD-I; BD-II) are among the
most common psychiatric ailments [1,2]. Patients with BD have poor life expectancies as these patients
have a decreased lifespan of about 9–17 years compared with the general population. Furthermore,
some studies from different countries (e.g., Denmark and UK) suggest that this mortality gap has
become larger over the last decades. Although the largest number of excess death cases in BD may
be attributed to natural (e.g., due to cardiovascular diseases or diabetes) and not unnatural causes,
suicide is also quite prevalent in the population of subjects with BD [1–5].
At a global scale, approximately 800,000 suicide deaths occur every year (which corresponds
to a global suicide rate of 11.4/100,000/year); thus, suicide may be considered a major public health
issue [6,7]. Although the great majority (≈90%) of suicide cases occur among subjects with major
mental—typically mood–disorders, the majority of patients with mood disorders never become
involved in suicidal behaviour. Accordingly, in addition to major mood disorders, other risk factors
(including special clinical features of the mental illness as well as some demographic, personality and
familial factors) should contribute to suicidality, which therefore should be deemed as a multicausal
phenomenon [2,8–10]. Hereinafter, we provide a concise summary of our current knowledge about
suicidality in BD based on a review of current literature (mainly review papers, book chapters,
meta-analyses, treatment guidelines of international societies, etc.).
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2. Epidemiology of Suicidal Behaviour in Bipolar Disorder
Suicidal behaviour is quite frequent among subjects with BD, as up to 4–19% of them ultimately
end their life by suicide, while 20–60% of them attempt suicide at least once in their lifetime [2]. In BD,
the risk of suicide death is up to 10–30 times higher than that of the general population [2,5,8,10–12].
The estimated annual suicide rate in patients with BD is about 200–400 / 100,000 [8]. BD-associated
cases account for about 3–14% of all suicide deaths [13].
It is important to mention that the ratio of suicide attempts to suicide deaths (i.e., the lethality
index) is much lower for patients with BD than for the members of the general population (one
study, for example, reported that rate as 35:1 and 3:1 for the general population and for BD patients,
respectively) [2,8,9]. A possible explanation for this phenomenon may be that BD subjects usually
employ more lethal suicide methods compared with members of the general population [2,8,9].
Nevertheless, attempts-to-suicide ratios lower than in the general population are not specific for BD,
as it is also observable for instance among patients with schizophrenia or major depressive disorder
(MDD) [2,14]. Unsurprisingly, suicidal ideation is also far more frequent in patients with BD (43%
past-year prevalence) than in the general population (9.2% life-time prevalence) [7,15].
Though it is indisputable that mood disorders are associated with markedly elevated levels
of suicidality, it is hard to pick out from the results of various studies whether there are relevant
differences in the risk of suicidal behaviour between different kinds of mood disorders. Accordingly,
higher, similar or lower levels of suicidality in BD patients compared to MDD patients have also been
reported [9,10,16]. In a similar fashion, based on the published information it is hard to disentangle
whether any BD subtype (BD-I or BD-II) is associated with a higher level of suicidality than the
other [2,8,11,16–19].
It is known that a relatively high proportion (8–55%) of patients with MDD has a history of
subthreshold hypomanic symptoms. This so called subthreshold bipolar subgroup of MDD patients
differs from MDD patients without subthreshold hypomanic manifestations in several ways. For
instance, a wide array of studies demonstrated that subthreshold bipolarity is associated with increased
levels of suicidality [20–23].
3. Risk Factors of Suicide in Bipolar Disorder
Several approaches exist to classify risk factors for suicide in BD. One of the most common systems
divides risk factors into proximal and distal ones, where proximal (or precipitating) factors are close to
suicidal behaviour in time whereas distal factors are rather considered as traits or predispositions and,
accordingly, they are enduring [10,24]. Other classifications assign suicide risk factors to conceptual
categories (e.g., risk factors associated with genetic or sociodemographic components or illness
characteristics or life events) [8,25,26]. Based on different conceptual backgrounds complex models
were conceived for the description of the whole process of suicide (e.g., the diathesis-stress model,
the bipolar suicidality model, the interpersonal theory of suicide, the three-step theory model or the
recently elaborated “neurocognitive model of suicide in the context of bipolar disorders”) [10].
In the current paper–without the ambition to be exhaustive–we list and briefly discuss the most
relevant risk and protective factors of suicide in BD. In regard to clinical history, previous suicide attempt(s)
is considered as one of the most powerful single predictors of future attempts and suicide death.
The period soon after hospital discharge may be characterized by extremely high levels of suicidality.
This finding draws attention to the importance of avoiding premature discharges and inappropriate
follow-ups. In addition, risk of suicide is increased during the period immediately after hospital admission.
Frequent and/or great number of prior hospitalizations are also associated with heightened risk of suicidal
self-harming behaviour. Early age at onset is also associated with suicidality in BD. The early years after
the diagnosis represent a high-risk period for suicide. Comorbidity with other psychiatric, addictive or
severe somatic disorders also increase the risk of all forms of suicidal behaviour. Rapid-cycling course
and predominant depressive polarity during the prior course are also associated with higher risks of
self-destructive behaviour. One of the most important determinants of suicidal behavior in BD is the
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type/polarity of the current mood episode/state: pure major depressive episodes and mixed states carry the
highest risk, while suicidal behaviour is rarely present in (euphoric) mania, hypomania and during
euthymic periods. However, some recent results indicated that there is no elevated risk of suicidal
behaviour during mixed state over the risk attributable to its depressed component. Furthermore,
these studies suggest that the majority of suicide risk elevation related to having previous mixed states
is not an aftermath of the mixed state itself, but can rather be attributed to a depression-predominant
course of the disorder. Longer duration of untreated illness (i.e., long time lag from the beginning of
the affective symptoms until treatment initiation) is also associated with higher hazards of suicidal
behaviour. Regarding sociodemographic factors, male gender is a risk factor for lethal suicides, while,
according to some results, female gender is a risk factor for attempts. These gender differences are
similar–but weaker–to those observable in the general population; accordingly, in this otherwise
high-risk population gender seems not to be a significant predictor for suicidal behaviour). Suicidality
is also more frequent among those bipolar subjects who are divorced, unmarried or single-parents or living
in social isolation. Age is a further important sociodemographic factor: BD subjects under 35 years of age
and above 75 years of age are at higher risk for engaging in suicide-related behaviours. Occupational
problems and unemployment also contribute to elevated levels of suicidality. Adversities in personal history
and acute stressors, such as experiencing sexual or physical abuse and parental loss in childhood or
bereavement, breaking the law/criminal conviction and financial disasters are important precipitants
of suicidality as well. Some personality attributes, for instance impulsive/aggressive traits, hopelessness
and pessimism also increase the risk of suicide. Certain types of affective temperaments (first and
foremost cyclothymic) have also been demonstrated to be associated with more frequent suicidal
behaviour in BD. Family history of suicide acts and/or major mood disorders are also strong risk factors
for suicide in subjects with BD. Some results also suggest that living in geographical locations where there
are large differences in solar insolation between winter and summer (i.e., near the poles) may be associated
with increased risks of attempted suicide in patients with BD-I [2,7,8,10–12,15,17,19,25–34].
4. Protective Factors of Suicide in Bipolar Disorder
In contrast to the above discussed several risk factors for suicide in BD, only a few protective
factors have been identified so far [2]. For instance good family and social support, parenthood and the
use of adaptive coping strategies seem to have some protective effects. Furthermore, a strong perceived
meaning of life and hyperthymic affective temperament are also a protective factors [2,10,24,29]. The possible
protective role of religiosity has emerged but results are somewhat inconclusive [2,26,35–37]. Last but
not least, it is important to note that treatment (and even more so a good response to treatment) is
protective against suicide in BD (see also the section “Suicide prevention in bipolar disorder”). In
consonance with the fact that treatment may decrease heightened suicidality, it is not surprising that
the majority of suicide victims are untreated affective disorder patients [8–11,13,38,39].
5. Suicide Prevention in Bipolar Disorder
From a pharmacological perspective, lithium seems to possess the greatest suicide-preventive potential
in patients with BD. Intriguingly, the suicide protective effect of lithium is not confined to bipolar
patients as it has also been demonstrated among patients with MDD (it is not surprising since, as we
have discussed it previously, a considerable proportion of “unipolar” MDD patients have subthreshold
bipolar features) [5,8,15,40–42]. Overall, compared to placebo, lithium appears to decrease the risk of
suicide by more than 60% in mood disorders [8,40,42]. Some results suggest that lithium is protective
against suicide, albeit in a decreased manner, even in those BD patients who are moderate/poor
responders to the phase-prophylactic effect of it. This finding may suggest that in the case of lithium
non-response in a patient who is at high risk for suicide, instead of switching lithium to another mood
stabilizer, the clinician should retain lithium (even in a lower dose) and combine it with another mood
stabilizer [1,41].
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A solid suicide-protective effect related to the administration of anticonvulsant-type mood stabilizers
(e.g., valproic acid, carbamazepine, lamotrigine) to BD patients has not been proven so far. On the
other hand, the concern of the FDA about the potential for an increased risk of suicidality associated
with anticonvulsants seems not to be applicable to patients with BD (i.e., in this population the use of
these agents is not associated with increased levels of suicidality). According to our current knowledge,
in regard to suicide prevention lithium is superior than these agents [2,8,15,41,43,44].
The role of antidepressants (ADs) in suicide prevention in individuals with BD seems to be negligible,
and, in fact, concerns have been raised that administration of ADs may increase suicidality in BD. It
is remarkable that findings are also inconsistent regarding the ability of ADs to prevent suicides in
patients with MDD. AD monotherapy should be avoided in BD [2,8,15,41].
Considering their increasing use in BD for instance as maintenance treatment, it is justifiable to ask
whether (atypical) antipsychotics have any beneficial effects on suicidal behaviour in BD. Unfortunately,
there are no high-quality data to answer this question at present, so further studies should elucidate
whether treatment with antipsychotics has any benefits in this respect [2,8,15,41].
Ketamin as a possible antidepressant agent has mainly been tested in patients with MDD and only
a few studies have been conducted among patients with bipolar depression. According to the results
of these small proof-of-concept investigations, ketamin shows similar antidepressive efficacy in bipolar
as in unipolar depression. In line with its possible efficacy, ketamin is recommended by the clinical
guideline of International College of Neuropsychopharmacology (CINP) for the treatment of bipolar
depression, but only as a fourth-line agent and in combination with a mood stabilizer. Similarly, until
now, the antisuicidal activity of ketamine was assessed mainly in MDD patients and only a small
number of investigations have been conducted in BD patients. These have mainly positive outcomes,
but further studies are needed to reveal whether ketamin has a similar antisuicidal effect in BD than in
MDD [45–51].
It is well-known that electroconvulsive therapy (ECT) shows a similar efficacy in the treatment
of depressive episodes in MDD and BPD (and some studies even found it more effective against
bipolar than unipolar depression). In line with its antidepressive effects, ECT is also considered as an
effective antisuicidal treatment modality, and it has been recently demonstrated that it is superior in
this regard to psychopharmacons both in unipolar and bipolar depression (and its antisuicidal efficacy
is comparable to the efficacy of psychopharmacons in bipolar mixed states and mania) [2,8,41,52,53].
Unfortunately, only a small number of studies have investigated up to now the efficacy of specific
(e.g., dialectical behavior therapy, cognitive-behavioural therapy, interpersonal and social rhythm
therapy) or unspecific (e.g., psychoeducation) psychosocial interventions against suicide among BD
patients. Nonetheless, results of the few existing studies are promising [2,8,54–58].
6. Summary and Clinical Implications
BD is a relatively common psychiatric disorder that is associated with increased mortality due
to both natural and unnatural causes. Accordingly, the risk of suicide is highly elevated in this
patient population. Because of this, a thorough assessment of suicide risk should take place at all
clinical visits. This clinical assessment should include, inter alia, the comprehensive examination of the
mental state, and the inquiry about the existence and features of current suicidal intents (e.g., duration
and intensity), the methods intended to be used, the access to means (e.g., weapons) as well as the
compliance to prescribed medications. In addition, it is essential to gain information about previous
suicidality. Whenever possible, hetero-anamnestic data should be gathered as well. The management
of suicidal behaviour in patients with BD represents a clinical challenge. Appropriate long-term
treatment of the disorder seems to be associated with the reduction of suicidality. Furthermore, in
acutely suicidal patients the removal of access to obvious means for suicide is essential and, in severe
cases, hospitalization may be justifiable as well. Prevention strategies should include the provision
of psychoeducation (for example, via information leaflets and/or by the members of the health care
staff) to the patients, as well as to relatives and friends, in order that they become able to recognize the
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warning signs of suicidal behaviour, be aware of the risk periods and the importance of adherence to
treatment, avoid isolation and call for help in emergency situations. A written list of sources of support
which are available during a suicidal crisis may also be helpful [2,10,15,59].
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